Survey on the Clinical Assessment of the Psychological Status of a Patient Over 75 Years Old in Oncology During the Realization of the G8 Score (CADEPO)

Depression Clinical Trial

— CADEPO  

Official title:

Survey on the Clinical Assessment of the Psychological Status of a Patient Over 75 Years Old in Oncology During the Realization of the G8 Score

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05681793
• Other study ID #: 2022-A02329-34
• Status: Completed
• Start date: January 17, 2023
• Est. completion date: April 2, 2023

Study information

• Verified date: June 2023
• Source: Hopital Nord Franche-Comte
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to make a statement concerning the identification of depressive symptoms at the time of the realization of the G8 score in patients over 75 with cancer and followed in oncology.

The main question it aims to answer are:

• Compare the medical hetero-evaluation of depressive symptoms via the G8 "neuro-psychiatric disorders" item score with a self-evaluation via the GDS-15 score

• Evaluate the number of patients over 75 treated with antidepressants

• Evaluate the proportion of patients with depressive symptoms according to the predisposing factors

• Compare the number of patients followed in oncogeriatrics over the period from 01/01/2022 to 02/28/2022 and the period from 01/01/2023 to 02/28/2023

Participants will complete a self-questionnaire (GDS-15 score) as well as a socio-demographic sheet.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: April 2, 2023
• Est. primary completion date: March 2, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years to 95 Years

Eligibility

Inclusion Criteria:

• Patients aged 75 and over

• Patients receiving treatment at the day hospital or oncology week hospital

• Patients informed and having not presented any opposition to their participation

Exclusion Criteria:

• Patients under the age of 75

• Patients under guardianship or curatorship

• Patients without social security

• Cognitive disorders compromising the understanding of the information and the performance of the study (in particular the completion of a self-administered questionnaire), in the opinion of the oncologist

Related Conditions & MeSH terms

• Depression

Locations

Country	Name	City	State
France	Hôpital Nord Franche-Comté	Trévenans

Sponsors (1)

Lead Sponsor	Collaborator
Hopital Nord Franche-Comte

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison the medical hetero-evaluation of depressive symptoms via the G8 "neuro-psychiatric disorders" item score with a self-evaluation via the GDS-15 score, in patients over 75 years of age with cancer and follow-up in oncology	Difference between the evaluation of the health professionals of the item "Neuropsychiatric problems" of the G8 score (no depression versus moderate or severe depression) and the responses of the patients to the self-administered questionnaire GDS-15 (Geriatric Depression Scale) ( 0 to 4: normal versus 5 to 15: moderate to severe depression).	2 months
Secondary	Evaluation of the number of patients over 75 on antidepressants included in this study	Percentage of patients included in this study and being treated with antidepressants	2 months
Secondary	Evaluation of the proportion of patients with depressive symptoms according to the predisposing factors with a sociodemographic sheet and from the medical file	Percentage of patients with depressive symptoms according to the predisposing factors (age, gender, housing in urban or rural areas,distance (in travel time) between the oncology department and home, social isolation, income, marital status, socio-professional category, type of cancer), taken from a sociodemographic sheet distributed to the patient and from the medical file	2 months
Secondary	Compare the number of patients followed in oncogeriatrics over the period from 01/01/22 to 02/28/22 and the period from 01/01/2023 to 02/28/2023	Percentage of patients followed in oncogeriatrics over the period from 01/01/2022 to 02/28/2022 and the period from 01/01/2023 to 02/28/2023	2 months